Unicycive Therapeutics (UNCY) Competitors

$8.73 +0.22 (+2.63%)

As of 02:54 PM Eastern

UNCY vs. IVA, ABUS, DRUG, EVMN, and ETON

Should you buy Unicycive Therapeutics stock or one of its competitors? MarketBeat compares Unicycive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Unicycive Therapeutics include Inventiva (IVA), Arbutus Biopharma (ABUS), Bright Minds Biosciences (DRUG), Evommune (EVMN), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Unicycive Therapeutics compare to Inventiva?

Unicycive Therapeutics (NASDAQ:UNCY) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Unicycive Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	342.94	-$26.56M	-$2.17	N/A
Inventiva	$5.07M	160.34	-$400.67M	N/A	N/A

Unicycive Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Unicycive Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 174.79%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 197.23%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Inventiva's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-146.30%	-94.84%
Inventiva	N/A	N/A	N/A

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 4 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for Unicycive Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat Unicycive Therapeutics' score of 0.18 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inventiva beats Unicycive Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Arbutus Biopharma?

Unicycive Therapeutics (NASDAQ:UNCY) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Unicycive Therapeutics and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Unicycive Therapeutics' score of 0.18 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Unicycive Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	342.94	-$26.56M	-$2.17	N/A
Arbutus Biopharma	$14.08M	60.48	-$33.50M	-$0.17	N/A

Unicycive Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 174.79%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 15.61%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Unicycive Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -237.88%. Arbutus Biopharma's return on equity of -42.39% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-146.30%	-94.84%
Arbutus Biopharma	-237.88%	-42.39%	-32.48%

Summary

Unicycive Therapeutics beats Arbutus Biopharma on 9 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Bright Minds Biosciences?

Unicycive Therapeutics (NASDAQ:UNCY) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Unicycive Therapeutics and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.18 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.35, indicating that its share price is 635% less volatile than the broader market.

Bright Minds Biosciences has lower revenue, but higher earnings than Unicycive Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	342.94	-$26.56M	-$2.17	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A

Unicycive Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 174.79%. Bright Minds Biosciences has a consensus price target of $128.60, indicating a potential upside of 60.40%. Given Unicycive Therapeutics' higher possible upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bright Minds Biosciences' return on equity of -28.62% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-146.30%	-94.84%
Bright Minds Biosciences	N/A	-28.62%	-28.08%

Summary

Bright Minds Biosciences beats Unicycive Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Evommune?

Unicycive Therapeutics (NASDAQ:UNCY) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 6 articles in the media. Evommune's average media sentiment score of 0.79 beat Unicycive Therapeutics' score of 0.18 indicating that Evommune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Unicycive Therapeutics has higher earnings, but lower revenue than Evommune. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	342.94	-$26.56M	-$2.17	N/A
Evommune	$10M	82.52	-$68.87M	-$9.50	N/A

Unicycive Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 174.79%. Evommune has a consensus price target of $49.25, indicating a potential upside of 114.97%. Given Unicycive Therapeutics' higher possible upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Evommune's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-146.30%	-94.84%
Evommune	N/A	N/A	N/A

Summary

Evommune beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Eton Pharmaceuticals?

Unicycive Therapeutics (NASDAQ:UNCY) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Unicycive Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -5.75%. Eton Pharmaceuticals' return on equity of -2.60% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-146.30%	-94.84%
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 6 mentions for Unicycive Therapeutics and 3 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.08 beat Unicycive Therapeutics' score of 0.18 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Unicycive Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	342.94	-$26.56M	-$2.17	N/A
Eton Pharmaceuticals	$79.95M	10.32	-$4.60M	-$0.18	N/A

Unicycive Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 174.79%. Eton Pharmaceuticals has a consensus target price of $39.33, indicating a potential upside of 30.41%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Unicycive Therapeutics beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$232.56M	$3.05B	$6.29B	$12.48B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-3.94	18.91	20.91	25.60
Price / Sales	342.94	281.93	548.78	75.41
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	6.19	4.36	9.87	6.72
Net Income	-$26.56M	$72.19M	$3.55B	$333.73M
7 Day Performance	11.12%	-0.91%	-0.24%	0.38%
1 Month Performance	25.85%	0.03%	1.44%	4.02%
1 Year Performance	56.44%	46.00%	41.01%	36.37%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	3.7773 of 5 stars	$8.73 +2.6%	$24.00 +174.8%	+40.5%	$232.56M	$680K	N/A	9	Earnings Report Analyst Forecast Analyst Revision
IVA Inventiva	2.8088 of 5 stars	$5.80 +0.0%	$16.56 +185.4%	+54.7%	$847.82M	$5.07M	N/A	100	Gap Up
ABUS Arbutus Biopharma	1.6856 of 5 stars	$4.29 -2.4%	$5.00 +16.7%	+35.1%	$843.89M	$14.08M	N/A	90	Earnings Report
DRUG Bright Minds Biosciences	2.5506 of 5 stars	$85.31 -1.4%	$128.60 +50.8%	+159.4%	$828.53M	N/A	N/A	N/A	Upcoming Earnings
EVMN Evommune	3.3216 of 5 stars	$22.61 -2.6%	$49.25 +117.9%	N/A	$814.23M	$13M	N/A	45	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. IVA, ABUS, DRUG, EVMN, and ETON

How does Unicycive Therapeutics compare to Inventiva?

Summary

How does Unicycive Therapeutics compare to Arbutus Biopharma?

Summary

How does Unicycive Therapeutics compare to Bright Minds Biosciences?

Summary

How does Unicycive Therapeutics compare to Evommune?

Summary

How does Unicycive Therapeutics compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. IVA, ABUS, DRUG, EVMN, and ETON

How does Unicycive Therapeutics compare to Inventiva?

Which has higher valuation and earnings, UNCY or IVA?

Which has more volatility and risk, UNCY or IVA?

Do analysts recommend UNCY or IVA?

Is UNCY or IVA more profitable?

Do insiders & institutionals have more ownership in UNCY or IVA?

Does the media favor UNCY or IVA?

Summary

How does Unicycive Therapeutics compare to Arbutus Biopharma?

Does the media favor UNCY or ABUS?

Do insiders & institutionals have more ownership in UNCY or ABUS?

Which has more volatility and risk, UNCY or ABUS?

Which has higher valuation and earnings, UNCY or ABUS?

Do analysts recommend UNCY or ABUS?

Is UNCY or ABUS more profitable?

Summary

How does Unicycive Therapeutics compare to Bright Minds Biosciences?

Does the media favor UNCY or DRUG?

Do institutionals & insiders have more ownership in UNCY or DRUG?

Which has more volatility & risk, UNCY or DRUG?

Which has better valuation & earnings, UNCY or DRUG?

Do analysts recommend UNCY or DRUG?

Is UNCY or DRUG more profitable?

Summary

How does Unicycive Therapeutics compare to Evommune?

Does the media refer more to UNCY or EVMN?

Do institutionals & insiders have more ownership in UNCY or EVMN?

Which has better valuation & earnings, UNCY or EVMN?

Do analysts recommend UNCY or EVMN?

Is UNCY or EVMN more profitable?

Summary

How does Unicycive Therapeutics compare to Eton Pharmaceuticals?

Is UNCY or ETON more profitable?

Does the media favor UNCY or ETON?

Which has more risk and volatility, UNCY or ETON?

Which has higher valuation & earnings, UNCY or ETON?

Do analysts rate UNCY or ETON?

Do insiders and institutionals have more ownership in UNCY or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools